INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Caligan Partners LP | 1,293,510 | $14,306,221 | 8.05% |
| DG Capital Management, LLC | 896,294 | $9,913,012 | 4.42% |
| Altium Capital Management LP | 323,000 | $3,572,380 | 2.70% |
| GREAT POINT PARTNERS LLC | 601,322 | $6,650,621 | 1.30% |
| Samsara BioCapital, LLC | 640,688 | $7,086,009 | 1.24% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $22,981,497 | 0.49% |
| DG Capital Management, LLC | 74,300 | $821,758 | 0.37% |
| AtonRa Partners | 18,581 | $205,506 | 0.32% |
| RIA Advisory Group LLC | 63,523 | $702,575 | 0.30% |
| Ikarian Capital, LLC | 160,200 | $1,771,813 | 0.28% |
| BOOTHBAY FUND MANAGEMENT, LLC | 941,755 | $10,415,810 | 0.23% |
| BOOTHBAY FUND MANAGEMENT, LLC | 846,700 | $9,364,502 | 0.20% |
| Virtus ETF Advisers LLC | 28,540 | $315,652 | 0.19% |
| Virtus Fund Advisers, LLC | 1,459 | $16,137 | 0.11% |
| Virtus Investment Advisers, Inc. | 9,297 | $102,825 | 0.07% |
| Skaana Management L.P. | 26,000 | $287,560 | 0.06% |
| JUPITER ASSET MANAGEMENT LTD | 472,847 | $5,224,959 | 0.06% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 861,801 | $9,531,519 | 0.06% |
| Skaana Management L.P. | 19,877 | $219,840 | 0.05% |
| PROFUND ADVISORS LLC | 73,688 | $814,989 | 0.04% |
External links
This page lists INTERCEPT PHARMACEUTICALS IN's shareholders in Q2 2023. To view INTERCEPT PHARMACEUTICALS IN's shareholder history, click here.